Drugs / TCR1672
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06213363 | Feb → Oct 2024 | respiratory system disorder | Beijing Tide Pharmaceutical Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TCR1672 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06213363 ↗ |
| Route | Oral | “TCR1672 Tablets will be administered orally after meal.” NCT06213363 ↗ |